Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
RPTX Repare Therapeutics
12.460-0.210-1.66%
Close
01/26 16:00 ET
12.020-0.440-3.53%
Post Mkt Price 01/26 16:35 ET
High
12.730
Open
12.730
Turnover
1.76M
Low
12.070
Pre Close
12.670
Volume
142.25K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Repare Therapeutics Inc. (RPTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Repare Gets ~$1.5M From Ono Pharma Under Research Pact
Repare Therapeutics Receives $1.5M Payment From Ono Pharmaceuticals
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that the Company has received an approximately $1.5 million (¥2
Repare Therapeutics (NASDAQ:RPTX) Trading Down 4%
Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) fell 4% on Tuesday . The stock traded as low as $12.92 and last traded at $12.92. 987 shares traded hands during trading, a decline of 99
Repare Therapeutics (NASDAQ:RPTX) Now Covered by Analysts at Capital One Financial
Capital One Financial initiated coverage on shares of Repare Therapeutics (NASDAQ:RPTX – Get Rating) in a research report report published on Friday morning, Briefing.com reports. The firm issued an
Repare Therapeutics Inc. (NASDAQ:RPTX) Receives $30.80 Average PT From Analysts
Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $14.55
Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) shares gapped down prior to trading on Friday . The stock had previously closed at $14.55, but opened at $13.89. Repare Therapeutics shares last tr
Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.
Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4%
Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) fell 4% during mid-day trading on Friday . The stock traded as low as $14.48 and last traded at $14.50. 4,560 shares changed hands during trading,
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Up to $14.25
Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $14.25, but opened at $14.74. Repare Therapeutic
Company Overview
More
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.
CEO： Mr. Lloyd M. Segal
Market： NASDAQ
Listing Date： 06/19/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet